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Abstract
Since the advent of monoclonal antibodies against epidermal growth factor receptor
(EGFR) in colorectal cancer therapy, the determination of RAS mutational status is needed
for therapeutic decision-making. Most prevalent in colorectal cancer are KRAS exon 2
mutations (40% prevalence); lower prevalence is observed for KRAS exon 3 and 4 muta-
tions (6%) and NRAS exon 2, 3, and 4 mutations (5%). The Idylla™ KRAS Mutation Test
on the molecular diagnostics Idylla™ platform is a simple (<2 minutes hands-on time),
highly reliable, and rapid (approximately 2 hours turnaround time) in vitro diagnostic sam-
ple-to-result solution. This test enables qualitative detection of 21 mutations in codons 12,
13, 59, 61, 117, and 146 of the KRAS oncogene being clinically relevant according to the
latest clinical guidelines. Here, the performance of the Idylla™ KRAS Mutation Assay, for
Research Use Only, was assessed on archived formalin-fixed paraffin-embedded (FFPE)
tissue sections by comparing its results with the results previously obtained by routine
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reference approaches for KRAS genotyping. In case of discordance, samples were
assessed further by additional methods. Among the 374 colorectal cancer FFPE samples
tested, the overall concordance between the Idylla™ KRAS Mutation Assay and the con-
firmed reference routine test results was found to be 98.9%. The Idylla™ KRAS Mutation
Assay enabled detection of 5 additional KRAS-mutated samples not detected previously
with reference methods. As conclusion the Idylla™ KRAS Mutation Test can be applied as
routine tool in any clinical setting, without needing molecular infrastructure or expertise, to
guide the personalized treatment of colorectal cancer patients.
Introduction
The Kirsten rat sarcoma viral oncogene (KRAS) belongs to a family of related RAS genes, com-
prising three known human isoforms, i.e., KRAS, NRAS, and HRAS [1, 2]. KRAS encodes the
KRAS protein, consisting of 188 or 189 amino acids (depending on exon 4 utilization), which
is a small membrane-boundGTPase that plays a pivotal role in cell signal transduction. Nor-
mally, KRAS exists in an inactive state. Ligand binding of a nearby transmembrane tyrosine
kinase receptor, like the epidermal growth factor receptor (EGFR), leads to activation of KRAS,
which is directly downstream of this receptor. Once in its active state, KRAS in turn activates a
wide variety of downstream effectors, hence influencing cell proliferation and cell survival.
Mutated KRAS remains in the active state, leading to a loss of its regulatory function on down-
stream effectors and eventually to cancer cell survival.
There are several etiological pathways leading to colorectal cancer, the traditional biomark-
ers beingmicrosatellite instability, the CpG island methylator phenotype, and somatic muta-
tions in BRAF and KRAS [3–5]. In a recent analysis of randomized controlled trials in
metastatic colorectal cancer patients, RAS mutation prevalence was found to be 55.9%, with
KRAS exon 2 mutations beingmost common (42.6% prevalence), followed by KRAS exon 4
(6.2%), NRAS exon 3 (4.2%), KRAS exon 3 (3.8%), NRAS exon 2 (2.9%), and NRAS exon 4
(0.3%) mutations [6]. The correspondingKRAS single amino acid missensemutations are
located at codons 12 or 13 for exon 2, codons 59 or 61 for exon 3, and codons 117 or 146 for
exon 4, with G12D (13.1% prevalence), G12V (11.6%), and G13D (8.1%) beingmost prevalent
in colorectal cancer.
Colorectal cancer is the secondmost common cause of cancer death in Europe, the third
most common cause in the US, and the fourth most common cause worldwide [5, 7, 8]. For
many years, intravenous 5-fluorouracil/leucovorinor oral capecitabine were the backbone of
first-line palliative chemotherapy for colorectal cancer [5, 9]. Since 2000, the addition to 5-fluo-
rouracil/leucovorin of oxaliplatin (FOLFOX) or irinotecan (FOLFIRI), or the combination of
capecitabine with oxaliplatin (CAPOX), led to increased response rates and survival.More
recently, the advent of targeted therapies including human vascular endothelial growth factor
(VEGF) and EGFRmonoclonal antibodies, expanded treatment options and further increased
treatment response. Thanks to the improvements in treatment and detection, 5-year colorectal
cancer survival rates increased significantly from about 50% in the 1970s to about 65% cur-
rently [8], while median overall survival of patients with metastatic disease increased from
8–12 months to 21–24 months [10].
Addition of the anti-EGFRmonoclonal antibody cetuximab or panitumumab to chemo-
therapy regimens improves outcome for metastatic colorectal cancer [9]. It was found that
presence of mutations in KRAS exon 2 (codon 12/13) considerably reduced the efficacy of
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these EGFR inhibitors [11, 12]. Exon 2 mutations have, therefore, been used as routine bio-
markers for predicting lack of response to cetuximab and panitumumab, thereby protecting
metastatic colorectal cancer patients from the undesirable side effects and the considerable cost
of ineffective therapy. As the presence of exon 2 mutations did not fully explain poor response
to anti-EGFR therapy, further analysis identified additional mutations predicting resistance,
i.e., mutations in KRAS exon 3 (codons 59 and 61) and 4 (codons 117 and 146), and in NRAS
exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146) [13–
15]. Hence, extended RAS analysis, beyond KRAS exon 2, is necessary to identify patients eligi-
ble for EGFR-targeted therapy. This is reflected by the latest clinical practice guidelines of the
European Society for Medical Oncology (ESMO) and the National Comprehensive Cancer
Network (NCCN) recommending genotyping of tumor tissue (primary or metastatic) for
the presence of KRAS exon 2 mutations as well as non-exon 2 mutations and NRAS mutations
[9, 16].
Various laboratory-basedor commercial KRASmutation assays are used in routine practice
and the majority of those have been optimized to be compatible with DNA extracted from for-
malin-fixed paraffin-embedded(FFPE) samples, which represent the most common form of
tumor tissue specimens [17]. However, these assays are characterized by differences in the
range of mutations covered, sensitivity, labor, cost, level of automation and multiplexing, and
in the need for specialized equipment and highly skilled staff. Importantly, it was recently
shown that KRAS genotyping results were only made available within 15 days for 82%, 51%,
and 98% of tested patients in Europe, Latin America, and Asia, respectively [18]. Since a time-
frame of 15 working days is undesirable, in particular for the therapeutic management of
rapidly progressing metastatic patients, shorter timelines are necessary. In some countries,
guidelines even require results to be available within 8 to 10 days [19].
The Idylla™ BRAFMutation Test, CE IVD, on the Idylla™ platform (Biocartis,Mechelen,
Belgium)was successfully launched for the fast and accurate detection of BRAF V600 muta-
tions in melanoma patients, directly on FFPE samples [20, 21]. More recently, the Idylla™
KRASMutation Test, CE IVD, which enables detection of 21 clinically relevant KRASmuta-
tions, was launched, and the Idylla™ NRASMutation Assay was made available for Research
Use Only. Unlike conventional methods that use time-consuming FFPE processing steps,
Idylla™ enables integration of pre-analytical and analytical processes in a single cartridge, thus
eliminating the need of manually and time-consuming successive deparaffinization, tissue
digestion, DNA extraction procedures, and PCR set-up steps.
Here, the results of a multi-center study testing archived FFPE tumor samples from colorec-
tal cancer patients for their KRASmutational status with the Idylla™ KRASMutation Assay
(RUO) are reported. To establish test performance, these results were compared to the results




Archived clinical FFPE materials of 374 colorectal cancer patients were selected for this study.
Samples were obtained from 12 European centers: KlinikumAugsburg (Augsburg, Germany;
n = 29), Hospital del Mar (Barcelona, Spain; n = 31), Queen ElizabethHospital (Birmingham,
UK; n = 32), Hôpital Erasme (Brussels, Belgium; n = 30), Rigshospitalet Copenhagen (Copen-
hagen, Denmark; n = 29), Royal London Hospital (London, UK; n = 31), Laboratoire National
de Santé (Dudelange, Luxembourg; n = 32), Niguarda Cancer Center (Milano, Italy; n = 34),
Institut du Cancer de Montpellier (Montpellier, France; n = 32), Oxford University Hospitals
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NHS Foundation Trust (Oxford, UK; n = 30), Surgical Pathology Unit (Padua, Italy; n = 30),
Centre Hospitalier Régional Universitaire de Tours (Tours, France; n = 34).
FFPE tissue sections (mostly 1 or 2, up to 12) of 5 μm to 25 μm thick were sampled as close
as possible (within the same FFPE block) to the sections used before to generate the reference
result (Fig 1). FFPE tissue sections were placed directly into the Idylla™ cartridge following the
assay instructions. Tumor content and area were determined on hematoxylin-eosin-stained
slides by a Pathologist and, if needed,macro-dissectionwas performed to achieve a tumor cell
content of at least 25%.
Artificial FFPE samples (i.e., FFPE Reference Standards fromHorizon Discovery, Cam-
bridge, UK) were included as external controls: 5 sites tested KRAS G12D at 5% allelic fre-
quency as well as KRAS G13D at 50% allelic frequency, 2 sites only tested KRAS G12D at 5%,
and 1 site only tested KRAS G13D at 50%.
In-House KRAS Mutation Tests Used as Reference Method
To guide cancer therapy, the KRASmutational status had been assessed previously on FFPE
material using routine reference methods. Depending on each center, different protocols were
used.
Sanger sequencing was used as a routine reference method by adopting different protocols
and equipment at each site.
Digital droplet PCR was performed on a QX100™ system (Bio-Rad Laboratories, Hercules,
CA) according to the instructions of the manufacturer.
High-resolutionmelting (HRM) analysis was performed following three different protocols:
(i) fragments from KRAS exon 2, 3, and 4 were PCR amplified using a Rotor-Gene 6000 instru-
ment (Qiagen) in combination with the LightCycler 480 High-ResolutionMelting Master
ReactionMix (Roche Diagnostics,Meylan, France); (ii) using an automated ABI Prism
7900HT SequenceDetection System (Life Technologies) according to the manufacturer’s rec-
ommendations; or (iii) using a LightCycler1 480 II (Roche) using the LightCycler1 480 High
ResolutionMelting Master Kit (Roche).
Pyrosequencingwas performed on a PyroMark Q24 MDx (Qiagen) following the manufac-
turer’s instructions.
Next-generation-sequencing (NGS) was performed as described [22], using the Ampliseq™
Colon and Lung Cancer panel (Life Technologies, Carlsbad, CA) for amplification and
sequencing of hotspot mutations in 22 lung and colon cancer relevant genes, and massively
parallel sequencing was carried out on an Ion Torrent Personal GenomeMachine sequencer
(Life Technologies) following the manufacturer’s instructions. Alternatively, the Multiplicom
(Niel, Belgium) Somatic 1Mastr v2 Colon Cancer Panel was used for amplification and
sequencing of the complete coding regions of the BRAF,KRAS, and NRAS genes, and massively
parallel sequencing was carried out on a MiSeq Sequencer (Illumina, San Diego, CA) following
the manufacturer’s instructions.
Commercial Routine KRAS Mutation Tests Used as Reference Method
At several centers to guide cancer therapy, the KRASmutational status had been assessed pre-
viously on FFPEmaterial using commercial routine tests.
The cobas1 KRASMutation Test (Roche), the Ion Torrent AmpliSeq™ Colon and Lung
Cancer Research Panel (Thermo Fisher Scientific), therascreen1 KRAS Pyro Kit (Qiagen), ther-
ascreen1 RAS Extension Pyro Kit (Qiagen), the KRAS, BRAF, PIK3CA Array (RandoxMolec-
ular, Crumlin,UK), and the QClamp™ KRAS Codon SpecificMutation DetectionKit (Exon 2,
3, 4) (DiaCarta,Hayward, CA), were performed according to the manufacturer’s instructions.
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Idylla™ KRAS Mutation Assay
The Idylla™ KRASMutation Assay enables mutation detection in exons 2, 3, and 4 of the KRAS
oncogene. This assay consists of five allele-specificmultiplex PCR reactions, designed for the
specific amplification of KRAS gene sequences with a mutation in codons 12, 13, 59, 61, 117, or
146. As such, the test enables detection of 21 KRASmutations, i.e., sevenmutations in exon 2
(codons 12 and 13), nine mutations in exon 3 (codons 59 and 61), and five mutations in exon 4
(codons 117 and 146) of the KRAS oncogene. All possible Idylla™ KRASMutation Assay
genetic call values are shown in Table 1. In case of multiple mutations, only the dominantly
detectedmutation (lowest ΔCq value) is currently reported.
FFPE tissue sectionswere placed directly into the cartridge of the fully automated Idylla™ plat-
form (Biocartis,Mechelen, Belgium) following the manufacturer’s instructions,without requiring
prior manual deparaffinizationor FFPE pre-processing. Briefly, after insertion of the FFPE tissue
section into the cartridge and insertion of the cartridge into the Idylla™ instrument, a combination
of reagents, enzymes, heat, and high intensity focusedultrasound (HIFU) induces deparaffiniza-
tion, disruption of the tissue, and lysis of the cells. The nucleic acids are liberated for subsequent
real-time PCR amplification. Allele-specificprimers and fluorescent probes are present in a stable
formulation. A sample processing control, involving the simultaneous amplification of a con-
served fragment in the intron 4 / exon 5 junctional region of the KRAS gene, was performed in
each of the five multiplex PCR reactions to check for adequate execution of the complete sample-
to-result process and as a measure for the amount of amplifiable DNA in the sample.
For every valid PCR curve, the Idylla™ software calculates a quantification cycle (Cq) value.
If the difference between the measured Cq for a KRASmutant PCR signal and the KRAS wild-
type Cq value, i.e. the ΔCq value, is within a validated range, the sample is characterized as
KRASmutation positive, and the specificmutation or mutation group is indicated. Samples
Fig 1. Decision tree of pre-analytical FFPE sample preparation prior to Idylla™KRAS Mutation Assay.
doi:10.1371/journal.pone.0163444.g001
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having a valid KRAS wild-type signal but a ΔCq value outside the validated range are reported
as being KRASmutation negative (wild-type). Results expressed as invalid are due to the pres-
ence of inhibitors in the sample, insufficient amplifiable DNA present in the sample, incorrect
placement of the sample in the cartridge, or a sample volume that is out of range. In addition,
incorrectly stored cartridges, use of cartridges that exceeded their in-use period after removal
from the pouch, or cartridgemalfunctioning can cause invalid results.
The results obtained with the Idylla™ KRASMutation Assay on archival material were not
used for diagnostic purposes of any kind.
Analytical Sensitivity and Specificity of Idylla™ KRAS Mutation Test
Both analytical sensitivity and specificity have been established for the Idylla™ KRASMutation
Test (CE IVD). Idylla™ KRASMutation Test (CE IVD) and Idylla™ KRASMutation Assay
(RUO) both consist of the same design and decision tree.
The test enables identifying the presence of a KRASmutation with a limit of detection
(LOD) of5% allelic frequency in a standard Horizon FFPE tissue section for the vast majority
of KRASmutations, while G12A, G13D, and A146P/T/V show LOD values of 9%, 10%, and
16%, respectively (Table 1).
The LOD is defined as the lowest KRASmutation copy number consistently detected in
95% of cases (with 95% confidence), at an allelic frequency of 5%. For KRASmutations
G12A, G12C, G12D, G12R, G12S, G12V, G13D, Q61H, Q61L, and A146T, dilution series were
prepared by blending liquefied KRASmutant FFPEmaterial with liquefiedKRAS wild-type
FFPEmaterial to the desired allelic frequency, and for mutations Q61K (c.180_181TC>AA),
Table 1. KRAS mutations detected by the Idylla™ KRAS Mutation Test.










2 12 G12C p.Gly12Cys c.34G>T G12C 5.0 3.6
G12R p.Gly12Arg c.34G>C G12R 5.0 0.5
G12S p.Gly12Ser c.34G>A G12S 5.3 2.5
G12A p.Gly12Ala c.35G>C G12A 9.1 3.2
G12D p.Gly12Asp c.35G>A G12D 5.0 13.1
G12V p.Gly12Val c.35G>T G12V 5.0 11.6
13 G13D p.Gly13Asp c.38G>A G13D 10.0 8.1
3 59 A59E p.Ala59Glu c.176C>A A59T/E/G 5.0 0.0
A59G p.Ala59Gly c.176C>G A59T/E/G 5.0 0.0
A59T p.Ala59Thr c.175G>A A59T/E/G 5.0 0.0
61 Q61K p.Gln61Lys c.181C>A Q61K 5.0 0.1
Q61K p.Gln61Lys c.180_181TC>AA Q61K 5.0 0.1
Q61L p.Gln61Leu c.182A>T Q61L/R 5.0 0.2
Q61R p.Gln61Arg c.182A>G Q61L/R 5.0 0.3
Q61H p.Gln61His c.183A>C Q61H 5.0 1.6
Q61H p.Gln61His c.183A>T Q61H 5.0 1.6
4 117 K117N p.Lys117Asn c.351A>C K117N 5.0 0.5
K117N p.Lys117Asn c.351A>T K117N 5.0 0.5
146 A146P p.Ala146Pro c.436G>C A146P/T/V 16.2 0.1
A146T p.Ala146Thr c.436G>A A146P/T/V 16.2 2.2
A146V p.Ala146Val c.437C>T A146P/T/V 16.2 0.5
a Individual mutations are shown as a percentage of the total number of mutations [6].
doi:10.1371/journal.pone.0163444.t001
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K117N (c.351A>T), and A59E (c.176C>A), synthetic target DNA was spiked to the desired
allelic frequency into liquefied KRAS wild-type FFPEmaterial. Two-fold dilution series were
prepared in 12-fold and tested with cartridges from two Idylla™ KRASMutation Test lots.
Mutation call rates were used to determine the LOD by logistic regression, and the correspond-
ing tissue area equivalent of an artificial FFPE specimenwith the allelic frequency as indicated
(Table 1) was deduced from these copy numbers. LOD values were verified by testing 20 repli-
cates at or below the upper limit of the 95% confidence interval.
In silico analysis of the human genome sequence did not identify reactivity for any of the oli-
gonucleotide primers outside the KRAS gene that could possibly result in non-specific ampli-
con formation and/or detection, thereby excluding cross-reactivity of Idylla™ KRASMutation
Test primers with sequence homologues in the NRAS gene or the KRASP1 pseudogene. Screen-
ing of single point mutations (SNPs) reported for the human KRAS gene by in silico analysis,
did not reveal any mutations outside the codons targeted by the Idylla™ KRASMutation Test
that could lead to false-positive results for KRAS. Known variants for the KRASmutations tar-
geted by the Idylla™ KRASMutation Test were identified in this in silico SNP analysis to be
detected and correctly reported by the assay. The only exceptions that will not be detected are
two rarely occurring variants for G12V and Q61R, respectively. Of the knownmutations
within the codons covered by the Idylla™ KRASMutation Test but for which the primers were
not primarily designed,mutation G12W will be detected and reported as G12C, and mutations
G13N and G13E will result in a G13D call.
Statistical Analysis
For method correlation, the one-sided 95% confidence intervals were calculated using theWil-
son method. Percentage agreement was calculated for the Idylla™ KRASMutation Assay
against routine reference methods.When comparing two methods, overall percent agreement
was calculated from the number of specimens tested positive and negative by both methods,
and the total number of specimens. Positive percent agreement was calculated from the num-
ber of specimens tested positive by both methods, and the total numbers of specimens tested
positive for the reference method. Negative percent agreement was calculated from the number
of specimens tested negative by both methods, and the total numbers of specimens tested nega-
tive for the reference method.
Results
Inter-Laboratory Reproducibility Idylla™ KRAS Mutation Assay
Artificial FFPE samples (i.e., FFPE Reference Standards fromHorizon Discovery)were included
as external controls: 5 sites tested KRASG12D at 5% allelic frequency and KRASG13D at 50%
allelic frequency, 2 sites only tested KRASG12D at 5%, and 1 site only tested KRASG13D at 50%.
The assay identified each of these mutations correctly (testing 1 replicate per mutation per
site). Hence, inter-laboratory reproducibility was 100% (based on 6 out of 6 G13D, and 7 out of
7 G12D).
Idylla™ KRAS Mutation Assay
Using the Idylla™ KRASMutation Assay, the KRASmutational status of 374 archived clinical
colorectal cancer FFPE samples was tested at 12 centers. The Idylla™ results were compared with
the original assessments made by routine reference methods (Tables 2 and 3, and S1 Table).
Several routine reference methods were used: cobas1 KRASMutation Test (Roche;
n = 119), Ion Torrent AmpliSeq™ Colon and Lung Cancer Research Panel (Life Technologies,
Idylla KRAS Mutation Assay Evaluation on Colorectal Cancer FFPE Tissue
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Table 3. Comparison between results of the Idylla™KRAS Mutation Assay and of routine reference methods (codon level).
Pyrosequencinga
WT c12 c13 c59 c61 c117 c146 Invalid Total
Idylla™ WT 51 2b 4 0 0 0 0 0 57
c12 1 35 0 0 0 0 0 1 37
c13 0 0 11 0 0 0 0 0 11
c59 0 0 0 1 0 0 0 0 1
c61 0 0 0 0 8 0 0 0 8
c117 0 0 0 0 0 2 0 0 2
c146 1 0 0 0 0 0 10 0 11
Invalid 0 1 1 0 0 0 0 0 2
Total 53 38 16 1 8 2 10 1 129
cobasc
WT c12/c13 c59 c61 c117 c146 Invalid Total
Idylla™ WT 44 4 0 0 0 0 0 48
c12 2 47 0 0 0 0 0 49
c13 0 14 0 0 0 0 0 14
c59 0 0 0 0 0 0 0 0
c61 1 0 0 4 0 0 0 5
c117 0 0 0 0 0 0 0 0
c146 3 0 0 0 0 0 0 3
Invalid 0 0 0 0 0 0 0 0
Total 50 65 0 4 0 0 0 119
NGSd
WT c12 c13 c59 c61 c117 c146 Invalid Total
Idylla™ WT 28 0 0 0 0 0 0 0 28
c12 0 13 0 0 0 0 0 0 13
c13 0 0 4 0 0 0 0 0 4
c59 0 0 0 2 0 0 0 0 2
c61 0 0 0 0 1 0 0 0 1
c117 0 0 0 0 0 1 0 0 1
c146 0 0 0 0 0 0 3 0 3
Invalid 0 0 0 0 0 0 0 0 0
Total 28 13 4 2 1 1 3 0 52
Overalle
WT c12 c13 c59 c61 c117 c146 Invalid Total
Idylla™ WT 129 4b 7 0 0 0 1 0 141
c12 3 138 0 0 0 0 0 1 142
c13 0 0 38 0 0 0 0 0 38
c59 0 0 0 5 0 0 0 0 5
c61 6 1 0 0 14 0 0 0 21
c117 0 0 0 0 0 4 0 0 4
c146 3 0 0 0 0 0 18 0 21
Invalid 0 1 1 0 0 0 0 0 2
Total 141 144 46 5 14 4 19 1 374
a therascreen1 KRAS Pyro Kit (Qiagen), therascreen1 RAS Extension Pyro Kit (Qiagen), in-house pyrosequencing.
b One of the samples contains double mutation G12A+G13R.
c cobas1 KRAS Mutation Test (Roche); detects mutations in codon 12/13 and in codon 61.
d Ion Torrent AmpliSeq™ Colon and Lung Cancer Research Panel (Life Technologies).
e Including results from other reference methods. For this analysis, codon 12/13 mutations detected by the cobas1 KRAS Mutation Test (Roche) were
categorized as codon 12 or codon 13 mutation, respectively, taking into account the mutation detected by the Idylla™ KRAS Mutation Assay, or by further
analysis (see below).
doi:10.1371/journal.pone.0163444.t003
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n = 52), therascreen1 KRAS Pyro Kit (Qiagen, n = 85), therascreen1 RAS Extension Pyro Kit
(Qiagen, n = 57), HRM screening (combined with the previous 2 therascreen1 kits, n = 34),
HRM screening and pyrosequencing (n = 32), HRM screening and Sanger (n = 34), Sanger
sequencing (as only method n = 59). Macro-dissectionwas performed in 141 cases to enrich
tumor area, in order to maximize sensitivity.
Of the 374 FFPE samples analyzed by the Idylla™ KRASMutation Assay, 231 tested positive
for a mutation in KRAS codon 12, 13, 59, 61, 117, or 146 (Table 4A): 13 samples with mutation
G12A, 18 with G12C, 57 with G12D, 5 with G12R, 10 with G12S, 39 with G12V, 38 with
G13D, 5 with A59T/E/G, 2 with Q61K, 8 with Q61L/R, 11 with Q61H, 4 with K117N, and 21
with A146P/T/V. In 141 cases no mutation was found, and an “invalid” call was reported in 2
cases with the Idylla™ KRASMutation Assay and in 1 case with the therascreen1 KRAS Pyro
Kit (Qiagen) (Table 4A). Overall, in this first assessment, agreement between the Idylla™ results
and the results of the routine reference methods was observed in 347 cases. These 347 cases
include 3 cases in which a different KRASmutation was identified by the Idylla™ KRASMuta-
tion Assay as compared to the routine reference method (Table 2). However, as treatment deci-
sions are driven by the mere absence or presence of a mutation in one of the relevant codons
and are not influenced by the exact nature of such a mutation, these 3 Idylla™ results were clas-
sified as being concordant.
In 12 cases, no KRASmutation was detected by the Idylla™ KRASMutation Assay while the
reference method had identified a mutation. In another 12 cases, the Idylla™ KRASMutation
Assay identified a mutation that had not been detected by the routine reference method. These
24 discordant samples were further analyzed (Table 5).
Discordant Results: Mutation Detected by Routine Reference Method
and Not By Idylla™ KRAS Mutation Assay
In FFPEmaterial of 12 colorectal cancer patients, a mutation in the KRAS oncogene previously
detected by a routine reference method was not detectedwhen reanalyzing the clinical archival
material with the Idylla™ KRASMutation Assay (Table 5).
Table 4. Comparison between results of the Idylla™KRAS Mutation Assay and (A) results of routine reference methods, or (B) results of routine
reference methods including further analysis.
(A) (B)
Routine reference methodsa Routine reference methods including
further analysisa
Mutation No mutation Invalid Total Mutation No mutation Total
Idylla™ Mutation 218 12 1 231 224 1 225
No mutation 12 129 0 141 3 134 137
Invalid 2 0 0 2 NA NA NA
Total 232 141 1 374 227 135 362
Idylla™ Performance Positive agreementb 94.78% (95% CI: 91.81% - 100%) 98.68% (95% CI: 96.74% - 100%)
Negative agreementb 91.49% (95% CI: 86.8% - 100%) 99.25% (95% CI: 96.75% - 100%)
Overall agreementb 93.53% (95% CI: 91.1% - 100%) 98.89% (95% CI: 97.56% - 100%)
NA, not applicable; 95% CI, 95% confidence interval.
a Different reference methods were used: cobas1 KRAS Mutation Test (Roche), Ion Torrent AmpliSeq™ Colon and Lung Cancer Research Panel (Life
Technologies), therascreen1 KRAS Pyro1 Kit (Qiagen), therascreen1 RAS Extension Pyro Kit (Qiagen), HRM screening and pyrosequencing, Sanger
sequencing, and HRM screening and Sanger sequencing; and for further analysis KRAS BRAF PIK3CA* Array (Randox Molecular), QClamp™ KRAS
Codon Specific Mutation Detection Kit (Exon 2, 3, 4) (DiaCarta), ddPCR, and Illumina NGS as well.
b Positive, negative, and overall agreement values were calculated not taking the invalids into account.
doi:10.1371/journal.pone.0163444.t004
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Bi_04 colon 6 1 20 398 no G12C no mutationh,e no mutationl,n C*




Au_18 metastasis 5 2 >50 15 yes no mutation G12Dd G12D 0.87%k D
Lo_23 colon 5 1 65 500 no no mutation codon 12/13e G13D 0.45%k D
Mo_14 colorectal 10 10 60 65 yes no mutation G13Df G13D 0.11%k D
Mo_32 colorectal 10 10 10 30 yes no mutation G12-G13>ARf no mutationk C
Mi_13 colon 10 1 50 225 no G12D no mutationg G12D 5.73%k C
Ox_13 colorectal 5 1 >50 50–600 yes G12V no mutatione G12V 1.8%k C
Pa_12 liver 10 1 40 70 no Q61R/L no mutationd Q61R 0.11%k C
Bi_15 liver 6 1 10 340 no A146P/T/V no mutationh,e A146Tn C
Mi_03 lymph
node
5 2 60 70 no Q61Hc no mutationg no mutationk,l C*
Mi_07 colon 10 1 60 125 no Q61Hc no mutationg no mutationk,l C*
Mi_31 colon 10 1 80 325 no Q61Hc no mutationg no mutationk,l C*
Mi_10 liver 5 2 60 50 no Q61Hc no mutationg ND X
Ox_28 colorectal 5 1 >50 50–600 yes Q61L/R no mutatione no mutationk D
Discordant results by design (i.e. mutation not detectable by method used)
Bi_01 liver 6 3 70 12 no no mutation G13Ci,e ND X
Bi_07 rectum 6 4 30 60 no no mutation G13Ci ND X
Co_13 colorectal 5 2 30 50 no no mutation codon 12/13e G13Co X
Mo_31 colorectal 10 10 50 140 yes no mutation G12Ff ND X
Pa_28 colorectal 10 1 35 94 no no mutation G13Rd ND X
To_19 colorectal 3 1 60 91 yes no mutation G13Cj ND X
Du_05 colorectal 10 1 40 100 no A146P/T/V no mutatione ND X
Lo_12 colon 5 1 90 250 no A146P/T/V no mutatione A146T
25.5%k
X
C, concordant; C*, concordant after Idylla™ KRAS Mutation Assay retesting; D, discordant; X, excluded from dataset; ND, not determined (in most cases
no tissue block left for further analysis).
a Retested three times with the Idylla™ KRAS Mutation Assay using one tenth of the original sample.
b Three times more input is used when retested with the Idylla™ KRAS Mutation Assay.
c Probably contamination issue in the laboratory.
d Sanger sequencing.
e cobas1 KRAS Mutation Test (Roche).
f HRM + pyrosequencing + Sanger sequencing.
g HRM + Sanger sequencing.
h therascreen1 KRAS Pyro Kit (Qiagen) + therascreen1 RAS Extension Pyro Kit (Qiagen).
i therascreen1 KRAS Pyro Kit (Qiagen)
j HRM + therascreen1 KRAS Pyro Kit (Qiagen).
k ddPCR.
l Idylla™ KRAS Mutation Assay retesting.
m Illumina NGS.
n KRAS, BRAF, PIK3CA* Array (Randox Molecular) and QClamp™ KRAS Codon Specific Mutation Detection Kit (Exon 2, 3, 4) (DiaCarta).
o Ion Torrent AmpliSeq™ Colon and Lung Cancer Research Panel (Life Technologies).
doi:10.1371/journal.pone.0163444.t005
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As the Idylla™ KRASMutation Assay is not intended to identifymutations G12F, G13C, or
G13R, the “no mutation” call for the 6 samples (Bi_01, Bi_07, Co_13,Mo_31, Pa_28, and
To_19) harboring one of these mutations was expected.Hence, no further analysis was per-
formed on 5 of these samples. For sample Co_13, the presence of a mutation in codon 13 but
with identity G13C was confirmed by NGS.
For sample Au_06, the presence of the A146T mutation detected earlier with Sanger
sequencing was confirmed by ddPCR, which detectedA146T with 29.7% allelic frequency.
Therefore, slices from the same FFPE block were retested three times with the Idylla™ KRAS
Mutation Assay using one tenth of the original sample, and each time an A146P/T/V call was
obtained. The exact reason why the Idylla™ KRASMutation Assay originallymissed this muta-
tion was not further investigated.
ddPCR confirmed the presence of mutation G12D in sample Au_18, although at an allelic
frequency (0.87%) below the LOD of the Idylla™ KRASMutation Assay for this mutation,
which may have been the reason for not detecting it with Idylla™. The allelic frequencymight
have decreasedwhen cutting further into the block.
In sample Lo_23, ddPCR confirmed the presence of G13D at low allelic frequency (0.45%),
which is below the LOD of the Idylla™ KRASMutation Assay for this mutation (10%).
Mutation G12A in sample Du_26 was not detected by the Idylla™ KRASMutation Assay,
while its presence was confirmed by both Illumina NGS (7.3% allelic frequency) and ddPCR
(4.7% allelic frequency). Because the allelic frequency value of G12A was around the LOD of
the Idylla™ KRASMutation Assay for this mutation (9%), insufficient sample input might be
the cause for not detecting the mutation at this level of allelic frequency. Retesting FFPE slices
of this sample with the Idylla™ KRASMutation Assay, while using three times more input
material, indeed resulted in successful detection of G12A.
In sample Mo_14, ddPCR confirmed the presence of mutation G13D, although at a low alle-
lic frequency (0.11%). Hence, the presence of this mutation in the sample was well below the
Idylla™ LOD for this mutation. Additionally, in this sample mutation V14I was identified by
HRM and pyrosequencing; the presence of this double mutation (G13D+V14I) in close vicinity
of each other most likely has affected detection by the Idylla™ KRASMutation Assay as well.
The Idylla™ KRASMutation Assay normally detects mutation G12A but not G13R, the pres-
ence of both mutations in close vicinity of each other in sample Mo_32 might have hindered
the detection of G12A. Moreover ddPCR did not confirm the presence of mutation G12A in
sample Mo_32, but this ddPCR result might also have been affected by the presence of the dou-
ble mutation.
Overall, in 4 samples (Au_18, Lo_23,Mo_14, and Mo_32), a mutation detected by a routine
reference method was not detected by the Idylla™ KRASMutation Assay. Of note, in three of
these cases, the mutation was present at an allelic frequency below the Idylla™ LOD, possibly
due to decreasing allelic frequencies when cutting further into the block.
Discordant Results: Mutation Detected by Idylla™ KRAS Mutation
Assay and Not By Routine Reference Method
In 12 of the archival clinical FFPE samples tested in this study, the Idylla™ KRASMutation Assay
identifiedmutations that were not identified by routine reference methods before (Table 5).
ddPCR analysis of the samples confirmed the mutations found by the Idylla™ KRASMuta-
tion Assay in 4 samples (Lo_12,Mi_13, Ox_13, and Pa_12). Although A146T was present in
an allelic frequency of 25.5% in sample Lo_12, the cobas1 KRASMutation Test (Roche) was
not able to detect this mutation, which is expected as this test is not designed for the identifica-
tion of mutations in codons 59, 117, and 146 of the KRAS oncogene.
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For sample Bi_15, the mutation identified by the Idylla™ KRASMutation Assay was con-
firmed by the KRAS, BRAF, PIK3CA Array (RandoxMolecular) and by the QClamp™ KRAS
Codon SpecificMutation DetectionKit (Exon 2, 3, 4) (DiaCarta).
In 3 samples (Mi_03, Mi_07, and Mi_31), ddPCR did not detect the Q61Hmutation identi-
fied by the Idylla™ KRASMutation Assay. Moreover, a repeat test of these samples did not
identify this mutation anymore either. Hence, the original discordance between the Idylla™
KRASMutation Assay and the routine reference methodmight have been due to a contamina-
tion issue in the laboratory. The results for sample Mi_10 might have been affected by the same
issue, however there was no material left for further analysis and possible confirmation of this
hypothesis.
For sample Du_05 no further analysis was performed as the “no mutation” call of the
cobas1 KRASMutation Test (Roche) for KRAS exon 4 mutations was expected. The Idylla™
KRASMutation Assay identifiedmutation A146P/T/V.
Concerning sample Bi_04, the Idylla™ KRASMutation Assay initially found mutation G12C
while the therascreen1 KRAS Pyro Kit (Qiagen) and therascreen1 RAS Extension Pyro Kit
(Qiagen) did not find this mutation. The “no mutation” finding was confirmed by the KRAS,
BRAF, PIK3CA Array (RandoxMolecular) and QClamp™ KRAS Codon SpecificMutation
DetectionKit (Exon 2, 3, 4) (DiaCarta). Retesting with the Idylla™ KRASMutation Assay did
no longer find the G12Cmutation.
In sample Ox_28, the initial cobas1 KRASMutation Test result was confirmed by ddPCR.
In total, in 5 samples (Bi_15, Lo_12,Mi_13, Ox_13, and Pa_12), the Idylla™ KRASMutation
Assay was able to identify a mutation that was not identified by the first-line routine reference
method but that was confirmed during further analysis.
Performance of the Idylla™ KRAS Mutation Assay
Further analysis enabled the identification of 8 samples (Bi_15, Mi_03, Mi_07, Mi_13, Mi_31,
Mo_32, Ox_13, and Pa_12) for which the Idylla™ KRASMutation Assay result was confirmed
by an independent reference method, and in 3 samples (Au_06, Bi_04, and Du_26) Idylla™
KRASMutation Assay retesting results were in agreement with the reference method result.
Therefore, the number of concordant samples was increased from 347 to 358 upon discordance
analysis.
The Idylla™ KRASMutation Assay is not intended to identify the rare mutations G12F,
G13C, or G13R (<0.5% prevalence in colorectal cancer), which were previously detected in 6
archival FFPE samples by routine reference methods. Despite the correct “no mutation
detected” Idylla™ call, these 6 samples (Bi_01, Bi_07, Co_13,Mo_31, Pa_28, and To_19) were
excluded from the dataset. Likewise, samples Du_05 and Lo_12 were excluded from the dataset
as the reference method used is not designed to detect the KRAS exon 4 mutation identified by
the Idylla™ KRASMutation Assay. Sample Mi_10 is removed from the dataset as there was no
material left to confirm the mutation found by the Idylla™ KRASMutation Assay, while a con-
tamination issue was suspected. Also the samples with invalid results for the Idylla™ KRAS
Mutation Assay (2 samples) or the reference method (1 sample) were removed from the data-
set. As a result, the total number of samples was reduced to 362.
Taking into account the additional concordant samples and the decreased number of sam-
ples in the dataset, the results obtained by the Idylla™ KRASMutation Assay were in agreement
with the confirmed reference method results in 358 out of 362 samples, resulting in an overall
concordance of 98.89% (95% confidence interval: 97.56% - 100%) (Table 4B). The negative
percent agreement was 99.25% (95% confidence interval: 96.75% - 100%) and positive percent
agreement was 98.68% (95% confidence interval: 97.74% - 100%).
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Discussion
The innovative Idylla™ KRASMutation Test, performed on the molecular diagnostic Idylla™
platform (Biocartis,Mechelen, Belgium), enables the qualitative detection in human colorectal
cancer FFPEmaterial of 21 KRASmutations being clinically relevant according to the latest
CAP/AMP/ASCO, ESMO, and NCCN guidelines [23]. These mutations encompass codons 12,
13, 59, 61, 117, and 146 of the KRAS oncogene.
Here, an analysis comparing the Idylla™ KRASMutation Assay (RUO) results with the origi-
nal assessments made by routine reference methods for determining the KRASmutational sta-
tus on FFPE samples is reported. Twelve clinical centers contributed to this study, and a total
of 374 archival clinical colorectal cancer FFPE samples were tested. The samples were specifi-
cally selected for this study; hence the mutational rates in the current sample set are not repre-
sentative for the incidence of KRASmutations in the general colorectal cancer patient
population. The results showed an overall presence of KRASmutations in the samples of
62.0% whenmeasured with routine reference methods and of 61.8%measured with the Idylla™
KRASMutation Assay, demonstrating that the sensitivity of the Idylla™ KRASMutation Assay
is comparable to the sensitivity currently used routine reference methods. The overall concor-
dance between the Idylla™ KRASMutation Assay and the confirmed reference routine test
results for colorectal cancer samples was found to be 98.9%, with a negative percent agreement
of 99.25% and a positive percent agreement of 98.68%.
The initial results showed discordances between results of the Idylla™ KRASMutation Assay
and of the original routine reference method for 24 of the 374 samples. In 12 of these 24 cases,
the Idylla™ KRASMutation Assay did not identify the KRASmutation that was previously
detected by the reference method, while in another 12 cases the Idylla™ KRASMutation Assay
identified a mutation not detected by the routine reference method. These 24 discordant sam-
ples were analyzed further to establish the overall concordance. Compared to pyrosequencing
(including in-housemethods, and the therascreen1 KRAS Pyro Kit and RAS Extension Pyro
Kit [Qiagen]), the cobas1 KRASMutation Test (Roche), and NGS (Ion Torrent AmpliSeq™
Colon and Lung Cancer Research Panel [Life Technologies]), the observed concordances var-
ied between 91.5% and 100% for these initial results.
Several reasons were found why the Idylla™ KRASMutation Assay did not identify KRAS
mutations detected earlier by routine reference methods. Six of the 12 specimens displayed
G13C, G12F, or G13R KRAS exon 2 mutations, which are not included in the Idylla™ KRAS
Mutation Assay because they are rarely observed (<0.5%) in the large colorectal cancer cohorts
published [24–26]. Four other samples exhibited G12A, G12D, or G13Dmutations according
to the reference results, but the observed allelic frequencies were below the LOD values of the
Idylla™ KRASMutation Assay (i.e., 9% for G12A, 5% for G12D, and 10% for G13D; Table 1);
in one of these samples, retesting with three times more input material indeed detected the
mutation. A decrease in allelic frequencywhen cutting further into the blockmight be an issue
in particularwhen using archival material. In one sample, the presence of an additional muta-
tion may have hindered the detection of the G12Amutation by the Idylla™ KRASMutation
Assay; interestingly, ddPCR could not confirm the presence of mutation G12A in this sample
either, demonstrating that the presence of a double mutation located in two consecutive codons
can affect allele-specific-basedtechniques. In addition, co-mutations for G12D and G13D have
exceptionally been described in colorectal cancer.
The other way around, the Idylla™ KRASMutation Assay identifiedmutations that were not
identified by routine reference methods in 12 archival clinical FFPE samples. Three of these
cases exhibited mutations with too low allelic mutation frequencies to be detected by the used
reference method (HRM, Sanger sequencing, or cobas1 KRASMutation Test), and two other
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cases displayed mutations not intended to be detected by the routine approach (i.e., KRAS
exon 4 mutations by the cobas1 KRASMutation Test). When considering all KRASmutations,
there was a strong agreement in detection rates between the Idylla™ KRASMutation Assay and
the routine reference methods. Overall, in 5 archival clinical samples, the Idylla™ KRASMuta-
tion Assay detected KRASmutations (confirmed by further analysis) which were not detected
by the routine reference methods previously used to guide therapy.
Of note, the Idylla™ KRASMutation Assay identified different KRASmutations in three
cases as compared to routine reference methods, but since treatment decisions are driven by
the presence of a mutation in the relevant codons and not by its exact nature, these results were
considered concordant.
According to manufacturer’s instructions, the minimal tumor cell percentage in samples for
the Idylla™ KRASMutation Assay should be at least 25% to guarantee reliable results. In case
this lower limit is not met, macro-dissection should be performed in order to enrich tumor
area (and thus tumor cells) and to maximize sensitivity. In the current study, macro-dissection
was performed in 141 cases.
It is now well established that the frequency of detected KRASmutations in colorectal can-
cer is influenced by the analytical sensitivity of the method applied for their detection. The sen-
sitivity of the Idylla™ KRASMutation Assay is comparable to most of the routine approaches
used in laboratories such as competitive allele-specificTaqman, amplification refractorymuta-
tion system-PCR,HRM, and pyrosequencing. These reference methods require process steps
including deparaffinization,DNA extraction, PCR amplification, and mutation detection,
which does not allow on demand testing and therefore leads to batch testing. Hence turn-
around times are more than a day, and even several days in the case of NGS. In addition, they
are labor-intensive, and require a specialized staff and complex infrastructure. The Idylla™
KRASMutation Assay is a simple and fast procedure that does not entail any special additional
equipment, has a very short hands-on time (i.e., less than 2 minutes) and has an estimated time
of approximately 2 hours from FFPE sample to the final reporting. Since the response time for
analyzing KRAS status might be a critical factor, in particular for patients with rapid disease
progression, the Idylla™ KRASMutation Assay could offer new prospects by significantly
decreasing turnaround time. Given the fact that the Idylla™ KRASMutation Assay can be easily
implemented in any pathology laboratory setting, even those without prior molecular diagnos-
tics experience, and needs a very short turnaround time to obtain test results, incorporation of
the KRASmutational status in the initial histological report is possible, enabling immediate ini-
tiation of targeted therapy. Although the Idylla™ KRASMutation Assay is not intended to
determine all possible KRASmutations or to quantify allelic frequency, the test is capable of
detecting the great majority of the relevant and most prevalent KRASmutations. However,
other techniques should be utilized to obtain quantitative information or complete overviews
of mutations present, or to discover new useful tumor biomarkers.
The Idylla™ KRASMutation Assay is a fully-automated and integrated real-time-PCR-based
test with high sensitivity, offering a “one-step” solution for routine application. Up-front sam-
ple preparation, apart from possible macro-dissection, is not necessary as FFPE tissue sections
are directly loaded into the single-use cartridge. As well, the interpretation of the results is fully
automated. Due to the platform characteristics, there is no need for additional molecular infra-
structure or a highly skilled staff to perform the test on site. Interestingly, the closure of the
leak-proof cartridge after loading the sample limits the risk of cross contamination between dif-
ferent samples. In large molecular laboratories, the Idylla™ KRASMutation Assay is considered
a useful addition to other technologies including NGS, in particular for urgent requests where a
very quick turnaround time is needed for occasional patients.
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Conclusion
In conclusion, the Idylla™ KRASMutation Test on the Idylla™ platform is to our knowledge
the only fully integrated and automated test for detection of 21 clinically relevant mutations
included in current guidelines starting from FFPE tissue samples and represents a relevant
solution for simple, highly reliable, and rapid routine determination of the KRASmutational
status needed to guide colorectal cancer therapy.
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